Moderna-Merck Cancer Vaccine Shows Promising Results in Late-Stage Trial

A groundbreaking clinical trial has yielded promising results for a new cancer treatment developed by Moderna and Merck. The personalized mRNA vaccine, combined with Keytruda, showed significant effectiveness in preventing melanoma from recurring compared to standard therapy.

The late-stage trial, which concluded on August 19, 2026, demonstrated that the treatment met its primary goal of reducing the risk of cancer recurrence.

This innovative approach represents a significant advancement in cancer research and treatment options for patients. The collaboration between Moderna and Merck has shown promise in harnessing the power of mRNA technology to combat cancer.